Search Results

You are looking at 1 - 10 of 6,327 items :

  • "Lung cancer" x
Clear All

. Chilingirova N, Balabanski L, Kurteva G, Toncheva D, Damyanov D, Chilingirov P. Detection of driver mutation heterogeneity in patients with non-small cell lung cancer (NSCLC) using next generation sequencing (NGS). EJC. 2015;51 Suppl 3:S612-S613. 5. Chilingirova N, Balabanski L, Ivanov S, Vazharova R, Toncheva D, Kurteva G. Detection of extensive driver mutation heterogeneity in 5 Bulgarian patients with adenosquamous carcinoma of the lung. Eur J Hum Genet. 2015;23(1). 6. Chilingirova N. [Non-small cell lung cancer in the era of precision medicine]. INSPIRO. 2017

References Gridelli C, Maione P, Rossi A, De Marinis F. The role of bevacizumab in the treatment of nonsmall cell lung cancer: current indications and future developments. Oncologist 2007; 12(10): 1183-1193. Dundar E, Oner U, Peker BC, Metintas M, Isiksoy S, Ak G. The significance and relationship between mast cells and tumour angiogenesis in non-small cell lung carcinoma. J Int Med Res 2008; 36(1): 88-95. Giaccone G. The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res 2007; 13(7): 1961-1970. Schiller JH, Harrington D

aromatic hydrocarbons inside the temples than in control workplaces (1). Incense smoke has been linked to lung cancer (2), upper respiratory tract carcinomas (3), nasopharyngeal carcinoma (4), childhood asthma (5), and leukemia (6). Lung cancer incidence rates among never-smoking women in Asia are among the highest in the world, even though most Asian women are never-smokers. The etiology of lung cancer among non-smoking women is still unclear. While much of the research focus has been on established risk factors such as household solid fuel use and environmental tobacco

1 Introduction Lung cancer results in more deaths than any other cancer, including breast, colon and prostate tumors. According to clinic pathology, lung cancer is divided into two categories: small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), with NSCLC being more common around the world. miRNAs have been identified to be closely related to cancer research and as of 2015, there were over 2500 miRNAs described in the human genome miRBase [ 1 ]. Generally, the function of miRNAs in cancer has been divided into two categories: oncogenic or tumor

. Oncologist. 2007 Jan;12(1):20–37 http://dx.doi.org/10.1634/theoncologist.12-1-20 [4] Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 1999 Nov 1;86(9):1867–1876 http://dx.doi.org/10.1002/(SICI)1097-0142(19991101)86:9<1867::AID-CNCR31>3.0.CO;2-9 [5] Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol. 2005 May 10;23(14):3175–3185 http://dx.doi.org/10.1200/JCO.2005.10.462 [6] Brambilla E, Travis WD, Colby TV, Corrin B

1 Introduction Lung cancer is the leading cause of cancer death worldwide [ 1 ]. Lung cancer is divided into two categories of non-small cell lung cancer (NSCLC) and small cell lung cancer. The clinical incidence of NSCLC is up to 75% [ 2 ]. Due to the lack of early detection of NSCLC, more than 80% of patients were diagnosed duringe the middle and late term [ 3 ]. Despite the continuous improvement of medical technologies such as surgical resection, adjuvant radiotherapy and chemotherapy, molecular targeted therapy and immunotherapy, the 5-year survival rate of

1 Introduction Approximately 150,000-170,000 patients with cancer develop into brain metastasis each year in the United States, making this the most common complication of systemic cancer. Lung cancer’s primary tumors are the most frequent source of brain metastases, accounting for approximately 48%-60% of all those diagnosed [ 1 ]. Brain metastases of patients with lung cancer include both non-small-cell (NSCLC) and small-cell (SCLC) histologists [ 2 ]. Brain metastases (BM) from non-small cell lung cancer (NSCLC) are about 20%, autopsy up to 40% [ 3

References 1. ICRP. (2010). Lung cancer risk from radon and progeny and statement on radon. (ICRP Publication 115). Ann. ICRP , 40 (1). ICRP 2010 Lung cancer risk from radon and progeny and statement on radon. (ICRP Publication 115) Ann. ICRP 40 1 2. Lubin, J. H., Boice, J. D., Edling, C., Hornung, R. W., Howe, G., Kunz, E., Kusiak, R. A., Morrison, H. I., Radford, E. P., Samet, J. M., Tirmarche, M., Woodward, A., Xiang, Y. S., & Pierce, D. A. (1994). Radon and lung cancer risk: A joint analysis of 11 underground miner studies. Bethesda, MD: U